MiniMed's post-spin growth positioning is clearer, with the product cycle and operating leverage supporting a Buy rating

Overview

This report summarizes the key takeaways from MiniMed Group at Goldman Sachs' 47th Annual Global Healthcare Conference. Management was represented by CEO Que Dallara and CFO Chad Spooner. The core message is that following its spin-off from Medtronic and recent IPO, the company has established a more independent growth strategy, product pipeline, and commercial channels. Goldman Sachs believes that recent performance and the first standalone guidance were both positive, reflecting years of strategic adjustment, a strong product cycle, and a differentiated competitive position created by parallel pharmacy and DME channels.

Core views

Goldman Sachs' core view is positive: first, MiniMed is undergoing an important product innovation cycle and reshaping both clinical perception and its consumer-facing brand; second, the company is relatively strong in overseas markets, with some innovations launching ahead of the U.S., while the U.S. timeline is catching up; third, management believes automated insulin delivery (AID) penetration is still in the early stages, leaving substantial room for patient conversion; fourth, GLP-1 is more likely to complement diabetes technology rather than replace devices such as pumps or smart pens; fifth, operating expense leverage has already been demonstrated over the past few years and still has room for further improvement after FY27.

Analysis framework

The report uses a conference-notes-style analytical approach, breaking down strategic positioning, product mix, recent operating and financial trends, ADA conference feedback, valuation, and downside risks based on management commentary. The valuation section forms the investment conclusion based on Goldman Sachs' sales forecasts and multiples, combined with the 12-month target price and coverage rating.

Methodology notes

• Valuation methodsSales multiple valuation

  1.8x GSe Q5-Q8 sales estimate

  Goldman Sachs' 12-month target price of $24 is based on 1.8x GSe Q5-Q8 sales estimates, appropriate for a medical technology company still in the stage of product expansion and accelerating growth.

• Factor analysisGS Factor Profile

  Comparison across four attributes: Growth, Financial Returns, Multiple, and Integrated

  Goldman Sachs' factor profile compares individual stocks with the market and industry peers across growth, financial returns, valuation multiples, and integrated metrics to provide investment context.

• M&A assessmentM&A Rank

  Potential acquisition probability rating from 1 to 3

  Goldman Sachs discloses that its globally covered stocks are assessed for potential M&A probability using qualitative and quantitative factors; 1 represents high probability, 2 medium probability, and 3 low probability.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• MINIMED GROUP INC (MMED.O)

  Core covered name

  Strengths

  Strong product innovation cycle, with a pipeline including Instinct, Flex, MiniMed GO, Fit, and Vivera; the pharmacy channel has the ability to directly track and deliver to patients while retaining the DME channel; management emphasizes the quality and differentiation of clinical data.

  Weaknesses

  Early FY27 product launches may dilute gross margin; growth requires incremental sales investment, especially investment in the PCP sales team following MiniMed GO; some cash flows may be somewhat uneven over the next few years.

  Comparison

  The report compares MiniMed within the diabetes technology and medical device coverage universe, noting a more intense competitive environment in insulin pumps, and related companies in the coverage universe include DexCom, Insulet, and Tandem Diabetes Care.

  Risks

  Slower-than-expected adoption among U.S. T2 patients, weaker-than-expected product portfolio execution, intensifying insulin pump competition, and safety or manufacturing issues.

Key data

• RatingBuyThe report explicitly states, We are Buy rated.
• 12-month target price$24Based on 1.8x GSe Q5-Q8 sales estimates.
• Disclosed price$14.23The parenthetical price following MiniMed Group in the company-specific regulatory disclosure.
• Target price history table price$14.92The target price history table shows the closing price on 31-Mar-26 as $14.92.
• FY27 revenue growth outlookHSD growthManagement stated that after adjusting for sales weeks, it is confident in achieving high-single-digit growth in FY27, with acceleration during the year.
• Operating expense leverageapproximately 300bpThe company said it has achieved about 300 basis points of operating expense leverage over the past few years.
• Cashapproximately $350 millionThe report states that the company is currently well capitalized, with approximately $350 million in cash.
• Growth track record11 quartersManagement said the company has delivered high-single-digit to low-double-digit growth for 11 consecutive quarters.

Impact & implications

From an investment perspective, MiniMed's key attraction lies in its more focused strategy after the spin-off, dense pipeline launches, and channel capabilities that help reach patients and support growth. If U.S. T2 adoption, Fit submission and CY27 launch, MiniMed GO rollout, and Flex volume ramp proceed smoothly, revenue growth and operating leverage could jointly drive valuation realization. However, early FY27 gross margin dilution from new products, increased selling investment, and intensifying competition may cause some stage-by-stage volatility in the earnings path.

Risks

• Adoption among the U.S. T2 diabetes population is slower than expected.
• Execution of the product portfolio and pipeline falls short of expectations.
• Competition in the insulin pump market continues to intensify.
• Unexpected safety or manufacturing challenges emerge.
• Early FY27 dilution from new products may put short-term pressure on gross margin.

What to watch

• Fit submission progress and the CY27 launch timeline.
• Commercial ramp-up of Flex, MiniMed GO, and Instinct in the U.S. market.
• AID patient conversion rates and the pace of adoption among the T2 population.
• Whether the complementary relationship between GLP-1 and diabetes technology continues to be accepted by clinicians and investors.
• The pace of recovery after FY27 gross margin bottoms out, and whether operating expense leverage can continue.
• MiniMed's channel execution, brand repositioning, and cash flow improvement after its standalone listing.